MSD Removes ‘Key Barrier’ To English Funding For Keytruda In Triple-Negative Breast Cancer
Executive Summary
MSD has agreed to restrict the use of its Keytruda combination therapy in a manner that means that Roche’s Tecentriq combination is no longer a direct comparator.